Literature DB >> 21273057

Young age and a positive family history of colorectal cancer are complementary selection criteria for the identification of Lynch syndrome.

P Manders1, L Spruijt, C M Kets, H W Willems, D Bodmer, K M Hebeda, I D Nagtegaal, J H J M van Krieken, M J L Ligtenberg, N Hoogerbrugge.   

Abstract

Families at high risk for Lynch syndrome can effectively be recognised by microsatellite instability (MSI) testing. The aim of the present study is to compare the effectiveness of a MSI test for the identification of Lynch syndrome in patients selected by a pathologist mainly based on young age at diagnosis (MSI-testing-indicated-by-a-Pathologist; MIPA), with that of patients selected by a clinical geneticist mainly based on family history (MSI-testing-indicated-by-Family-History; MIFH). Patients with a Lynch syndrome associated tumour were selected using MIPA (n=362) or MIFH (n=887). Germline DNA mutation testing was performed in 171 out of 215 patients (80%) with a MSI positive tumour. MSI was tested positive in 20% of the MIPA-group group compared to 16% in the MIFH-group (P=0.291). In 91 of 171 patients with MSI positive tumours tested for germline mutations were identified as Lynch syndrome patients: 42% in the MIPA-group and 56% in the MIFH-group (P=0.066). Colorectal cancer (CRC) or endometrial cancer (EC) presenting at an age below 50 years would have led to the diagnosis of Lynch syndrome in 89% of these families (CRC below 50 years: 88% and EC below 50 years: 12%). Families detected by MIPA were characterised more often by extracolonic Lynch syndrome associated malignancies, especially EC (P<0.001). Our results indicate that recognition of Lynch syndrome by CRC or EC below 50 years is as effective as a positive family history. Families from patients selected by individual criteria more often harbour extracolonic Lynch syndrome associated malignancies.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21273057     DOI: 10.1016/j.ejca.2010.12.024

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

1.  Can a gastrointestinal pathologist identify microsatellite instability in colorectal cancer with reproducibility and a high degree of specificity?

Authors:  Eli Brazowski; Paul Rozen; Sara Pel; Ziona Samuel; Irit Solar; Guy Rosner
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

Review 2.  Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD).

Authors:  Erika K S M Leenders; Harm Westdorp; Roger J Brüggemann; Jan Loeffen; Christian Kratz; John Burn; Nicoline Hoogerbrugge; Marjolijn C J Jongmans
Journal:  Eur J Hum Genet       Date:  2018-06-14       Impact factor: 4.246

3.  Acceptance of genetic counseling and testing in a hospital-based series of patients with gynecological cancer.

Authors:  Nicky Dekker; Eleonora B L van Dorst; Rob B van der Luijt; Marielle E van Gijn; Marc van Tuil; Johan A Offerhaus; Margreet G E M Ausems
Journal:  J Genet Couns       Date:  2012-11-30       Impact factor: 2.537

4.  Anticipation in lynch syndrome: where we are where we go.

Authors:  Cristina Bozzao; Patrizia Lastella; Alessandro Stella
Journal:  Curr Genomics       Date:  2011-11       Impact factor: 2.236

Review 5.  Opportunities for immunotherapy in microsatellite instable colorectal cancer.

Authors:  Harm Westdorp; Felix L Fennemann; Robbert D A Weren; Tanya M Bisseling; Marjolijn J L Ligtenberg; Carl G Figdor; Gerty Schreibelt; Nicoline Hoogerbrugge; Florian Wimmers; I Jolanda M de Vries
Journal:  Cancer Immunol Immunother       Date:  2016-04-08       Impact factor: 6.968

6.  An Escherichia coli effector protein promotes host mutation via depletion of DNA mismatch repair proteins.

Authors:  Oliver David Kenneth Maddocks; Karen Mary Scanlon; Michael S Donnenberg
Journal:  MBio       Date:  2013-06-18       Impact factor: 7.867

7.  Efficient and reproducible identification of mismatch repair deficient colon cancer: validation of the MMR index and comparison with other predictive models.

Authors:  Patrick Joost; Pär-Ola Bendahl; Britta Halvarsson; Eva Rambech; Mef Nilbert
Journal:  BMC Clin Pathol       Date:  2013-12-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.